Search results for "immunology and allergy"

showing 8 items of 2868 documents

Editorial: Thymic Epithelial Cells: New Insights Into the Essential Driving Force of T-Cell Differentiation.

2021

thymic stromal cellsT-LymphocytesImmunologyThymus GlandBiology03 medical and health sciences0302 clinical medicinethymusmedicineImmunology and AllergyAnimalsHumansImmunodeficiency030304 developmental biologycentral tolerance0303 health sciencesCell DifferentiationEpithelial CellsRC581-607medicine.diseaseCell biologyEditorialT cell differentiationthymic epithelial cellsCentral toleranceImmunologic diseases. Allergyimmunodeficiency030215 immunologyFrontiers in immunology
researchProduct

Interferon α interferes with immunological tolerance.

2013

The ability of regulatory T cells (Tregs) to promote immunological tolerance represents an important obstacle in cancer immunotherapy. We have recently discovered that the clinically established immunotherapeutic agent interferon α (IFNα) inactivates the suppressive functions of human Tregs. Here, we outline the mechanisms whereby IFNα mediates this important function and discuss its therapeutic implications for cancer immunotherapy.

tolerancebusiness.industrymedicine.medical_treatmentImmunologyImmunotherapeutic agentCancerNK cellsmedicine.diseasePDEregulatory T cellsIfn alphaOncologyCancer immunotherapyInterferon αcAMPImmunologymedicineImmunology and AllergycancerIFN-alphabusinessAuthor's ViewFunction (biology)Oncoimmunology
researchProduct

Mast cells as protectors of health.

2019

Mast cells (MCs), which are well known for their effector functions in T(H)2-skewed allergic and also autoimmune inflammation, have become increasingly acknowledged for their role in protection of health. It is now clear that they are also key modulators of immune responses at interface organs, such as the skin or gut. MCs can prime tissues for adequate inflammatory responses and cooperate with dendritic cells in T-cell activation. They also regulate harmful immune responses in trauma and help to successfully orchestrate pregnancy. This review focuses on the beneficial effects of MCs on tissue homeostasis and elimination of toxins or venoms. MCs can enhance pathogen clearance in many bacter…

tumorImmunologyvenomTryptaseMast cell; innate immunity; infection; mast cell protease; tumor; pregnancy; venom; toxin; central nervous system traumaInfectionsCell DegranulationMast Cell ; Innate Immunity ; Infection ; Mast Cell Protease ; Tumor ; Pregnancy ; Venom ; Toxin ; Central Nervous System TraumaImmune systemCathelicidinsPregnancymedicineImmunology and AllergyAnimalsHomeostasisHumansEmbryo ImplantationMast CellsCNS traumatoxininnate immunityTissue homeostasismast cell proteaseToll-like receptorTumor microenvironmentInnate immune systembiologybusiness.industryDegranulationMast cellhumanitiesImmunity InnateToll-Like Receptor 2infectionddc:medicine.anatomical_structureImmunologybiology.proteinFemalepregnancybusinessmast cell
researchProduct

Real-world experience with obeticholic acid in patients with primary biliary cholangitis

2021

Background & aims Obeticholic acid (OCA) is the second-line treatment approved for patients with primary biliary cholangitis (PBC) and an inadequate response or intolerance to ursodeoxycholic acid. We aimed to evaluate the effectiveness and safety of OCA under real-world conditions. Methods Patients were recruited into the Italian PBC Registry, a multicentre, observational cohort study that monitors patients with PBC at national level. The primary endpoint was the biochemical response according to Poise criteria; the secondary endpoint was the biochemical response according to normal range criteria, defined as normal levels of bilirubin, alkaline phosphatase (ALP), and alanine aminotransfer…

upper limit of normalCirrhosisALTAMAAutoimmunityantinuclear antibodiesULNPBCGastroenterologyUDCASettore MED/12ULN upper limit of normalobeticholic acidaRR adjusted risk ratio.CRFs case record formAST aspartate transferaseClinical endpointGGT gamma-glutamyl transferaseQCprimary biliary cholangitisGastroenterologyUrsodeoxycholic acidANATCCCirrhosisCholestasiTIPSTreatment Completer CohortANA antinuclear antibodiemedicine.medical_specialtyRRUDCA ursodeoxycholic acidTIPS transjugular intrahepatic portosystemic shuntOCACirrhosiALP alkaline phosphataseautoimmune hepatitismedicine.diseasedigestive system diseasesDiscontinuationKeywords: AIH autoimmune hepatitiQC quality controlchemistrygamma-glutamyl transferaserandomised controlled trialelectronic data captureantimitochondrial antibodiesaspartate transferaseAutoimmune hepatitischemistry.chemical_compoundAIHCRFsImmunology and Allergyadjusted risk ratioANA antinuclear antibodiesRR risk ratioOverall cohortALT alanine transferaseAMA antimitochondrial antibodieCholestasisCRFs case record formsObeticholic acidOverlap PBC-AIHursodeoxycholic acidOCA obeticholic acidTolerabilityalkaline phosphataseRCTResearch Articlemedicine.drugcase record formsContext (language use)AMA antimitochondrial antibodiesInternal medicineEDC electronic data capturetransjugular intrahepatic portosystemic shuntInternal MedicinemedicineRCT randomised controlled trialaRR adjusted risk ratioOClcsh:RC799-869quality controlalanine transferaseASTaRRHepatologybusiness.industryAutoimmunity; Cholestasis; Cirrhosis; Overlap PBC-AIHAIH autoimmune hepatitisTCC Treatment Completer CohortPBC primary biliary cholangitiGGTrisk ratioOC Overall cohortALPlcsh:Diseases of the digestive system. GastroenterologyPBC primary biliary cholangitisbusinessEDC
researchProduct

Could PD-1/PDL1 immune checkpoints be linked to HLA signature?

2019

The outstanding clinical expansion of monoclonal antibodies (mAbs) to programmed cell death receptor-1 (PD-1) (nivolumab and pembrolizumab) and PD-1 ligand-1 (PDL-1) (atezolizumab, avelumab and durvalumab) has received an increasing level of interest regarding immunotherapy and multidrug combinations, for the treatment of a number of common human malignancies. Some patients treated with these agents receive remarkable benefits in term of quality of life, progression-free (PFS) and overall survival (OS). However, a significant percentage of these patients experience immune-related adverse events (irAEs), while others present with an ultra-rapid disease progression, defined as hyperprogressio…

vDrug-Related Side Effects and Adverse ReactionsProgrammed Cell Death 1 ReceptorImmunologyAntibodies Monoclon alHuman leukocyte antigenB7-H1 AntigenImmune systemHLA AntigensirAENeoplasmsHumansImmunology and AllergyMedicinePD-1/PDL-1-blockadebusiness.industryAntibodies MonoclonalBiomarkerProgrammed Cell Death 1 ReceptorSignature (logic)HaplotypesOncologyImmunologyoutcomeImmunotherapyHLA alleleDrug-Related Side Effects and Adverse ReactionbusinessBiomarkersB7-H1 AntigenImmunotherapy
researchProduct

Translocation of the nuclear autoantigen La to the cell surface of herpes simplex virus type 1 infected cells.

1992

Recently we developed a procedure to translocalize one of the extractable nuclear antigens (ENAs), the La protein, to the cell surface of CV-1 cells. Here we report that herpes simplex virus type 1 infection can also induce a translocation of the autoantigen to the cell surface. On the cell surface we detected La protein assembled with large protrusions. Within these protrusions La protein colocalized with virus particles. These protrusions are known to be released from the cell after virus infections. Such complexes consisting of self and virus could provide helper determinants for an anti-self response, and therefore be important in generation of autoimmunity.

virusesImmunologyCellmedicine.disease_causeAutoantigensVirusHerpesviridaeSingle-stranded binding proteinAntigenAlphaherpesvirinaeCricetinaemedicineImmunology and AllergyAnimalsNuclear proteinCells CulturedCell NucleusbiologyAntibodies MonoclonalBiological TransportHerpes Simplexbiology.organism_classificationBlood Physiological PhenomenaVirologymedicine.anatomical_structureHerpes simplex virusRibonucleoproteinsbiology.proteinAutoimmunity
researchProduct

The human autoantigen La/SS-B accelerates herpes simplex virus type 1 replication in transfected mouse 3T3 cells.

1998

SUMMARY Permanently transfected mouse cell lines which expressed different levels of the human autoantigen La/SS-B were infected with different strains of herpes simplex virus type 1, including the strains ANG, HSZP, 17syn+ and HFEM. During infection the localization of the human La protein was followed using an anti-La MoAb, which recognized only the human La protein but did not cross-react with either the endogenous mouse La protein or any viral encoded protein. After infection La protein was transported from the nucleus to the cytoplasm. The time course of translocation was dependent on the amount of human La protein expressed in the respective cell line. Moreover, acceleration of viral …

virusesImmunologyHerpesvirus 1 Humanmedicine.disease_causeTransfectionVirus ReplicationAutoantigensVirus3T3 cellsSingle-stranded binding proteinMicemedicineImmunology and AllergyAnimalsHumansbiologyTransfection3T3 CellsOriginal ArticlesHerpes simplex virusmedicine.anatomical_structureViral replicationGene Expression RegulationRibonucleoproteinsCytoplasmCell cultureImmunologybiology.proteinClinical and experimental immunology
researchProduct

Immune responses during COVID-19 infection

2020

International audience; Over the past 16 years, three coronaviruses (CoVs), severe acute respiratory syndrome CoV (SARS-CoV) in 2002, Middle East respiratory syndrome CoV (MERS-CoV) in 2012 and 2015, and SARS-CoV-2 in 2020, have been causing severe and fatal human epidemics. The unpredictability of coronavirus disease-19 (COVID-19) poses a major burden on health care and economic systems across the world. This is caused by the paucity of in-depth knowledge of the risk factors for severe COVID-19, insufficient diagnostic tools for the detection of SARS-CoV-2, as well as the absence of specific and effective drug treatments. While protective humoral and cellular immune responses are usually m…

virusesReviewmedicine.disease_causeDiagnostic toolsSeverity of Illness Index[SDV.IMM.II]Life Sciences [q-bio]/Immunology/Innate immunityimmune responsehumoral0302 clinical medicineRisk Factors[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesImmunology and AllergyRC254-282Coronavirus[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseasesImmunity Cellular[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseasesNeoplasms. Tumors. Oncology. Including cancer and carcinogensvirus diseases3. Good healthOncologySevere acute respiratory syndrome-related coronavirus[SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology030220 oncology & carcinogenesis[SDV.IMM.IA] Life Sciences [q-bio]/Immunology/Adaptive immunologyMiddle East Respiratory Syndrome Coronavirus[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesCovid-19Coronavirus disease 2019 (COVID-19)Sars-CoV-2Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Immunology03 medical and health sciencesImmune systemIntensive caremedicineHumans[SDV.IMM.II] Life Sciences [q-bio]/Immunology/Innate immunityHost Microbial Interactionsbusiness.industryRC581-607Protective Factorsbiochemical phenomena metabolism and nutritionmedicine.diseaseimmunityImmunity HumoralClinical trialCoronavirusImmunologyMiddle East respiratory syndromeImmunologic diseases. Allergybusinesscellular030215 immunology
researchProduct